Rigor Reviewed

Rigor-Reviewed Manuscript

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.

Name: Αlpha¹ Rigor Record — Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
Item: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
Rating: 96
Author: Αlpha¹

McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 5 high issues for “Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
CitationsCitations & links (capped) ×24−1★
ReportingEthical approvals partially met−0.25★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Ethics/consent reporting incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 2 randomized controlled trial with a strong scientific premise, rigorous design, and transparent reporting. The main weakness is the missing explicit ethics approval statement, and there are minor reporting gaps (randomization method, power analysis, CONSORT adherence).

Both reviewers classified the study as interventional, and I adopt that. The evaluation covered all eight dimensions; non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only a subset of tests (6 recomputed), so the statistical analysis is not fully verified.

7 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple studies on IL-17A/IL-17F dual blockade, bimekizumab efficacy, and the size limitations of monoclonal antibodies. It clearly links the premise to the study objective of evaluating sonelokimab, a nanobody with dual IL-17A/F inhibition. The limitations of prior research (e.g., incomplete MDA achievement with bimekizumab, size-related tissue penetration issues) are explicitly addressed as motivation for the study.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on IL-17 in PsA, the limitations of current biologics, and the rationale for nanobodies.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Clinically, dual blockade of IL-17A and IL-17F with the monoclonal antibody (mAb) bimekizumab has been shown to be superior to inhibiting IL-17A alone with secukinumab in plaque psoriasis.”

paraphrase[Introduction, paragraph 4]

“Nanobodies have multiple potential advantages over traditional antibodies, including their smaller size and multi-target design potential.”

direct quote[Introduction, paragraphs 3-4]

“One limitation with current biologics may be the size of the therapeutic immunoglobulin G1 antibodies (typically around 150 kDa) that block inflammatory signaling.”